Innovations for Healthy Living - Improving Minority Health and Eliminating Health Disparities (R43/R44 - Clinical Trial Optional) | RFA MD 23 003

Opportunity Information: Apply for RFA MD 23 003

The Innovations for Healthy Living - Improving Minority Health and Eliminating Health Disparities (R43/R44 - Clinical Trial Optional) opportunity, listed as RFA-MD-23-003, is a National Institutes of Health (NIH) Small Business Innovation Research (SBIR) funding announcement aimed at pushing new, practical innovations toward commercialization. The main focus is on developing a product, process, or service that can measurably improve minority health and/or reduce (and ultimately eliminate) health disparities affecting one or more population groups that NIH recognizes as experiencing health disparities. In plain terms, this program is looking for small businesses that can turn an idea into something usable in the real world, with the end goal of narrowing longstanding gaps in health outcomes.

This FOA is structured under the SBIR mechanism using the R43/R44 grant activity codes, which generally align with the typical SBIR phases. R43 commonly corresponds to earlier-stage feasibility and proof-of-concept work (often thought of as Phase I), while R44 generally supports more advanced research and development aimed at moving a validated concept closer to a market-ready solution (often thought of as Phase II). The label "Clinical Trial Optional" means applicants may propose projects that include a clinical trial if it makes sense for the technology and stage of development, but a clinical trial is not required. That flexibility is important for innovations that might be preclinical, engineering-focused, implementation-oriented, or otherwise not yet at a point where a clinical trial is appropriate.

The projects NIH is seeking should be grounded in real-world practicality, not just scientific novelty. The FOA emphasizes that appropriate technologies should be effective, affordable, and culturally acceptable, which signals that reviewers will likely pay attention to whether the proposed solution can actually be adopted and sustained in the communities experiencing disparities. A strong application would typically connect the innovation to a clearly defined health disparity problem, explain why current approaches fall short, and show how the proposed solution fits the needs, preferences, constraints, and lived realities of the target population. The commercialization orientation also suggests that applicants should be thinking about product-market fit, adoption barriers, distribution channels, reimbursement or payment models (when relevant), and how the innovation could realistically be scaled.

Eligibility is limited to eligible United States small business concerns, consistent with SBIR rules. Foreign institutions cannot apply, and non-U.S. components of U.S. organizations are also not eligible to apply. That said, the announcement notes that foreign components, as defined by the NIH Grants Policy Statement, may be allowed in some circumstances, which typically means a U.S. applicant might justify a limited foreign component if it is clearly necessary for the project and complies with NIH policy. Still, the core applicant organization must be a qualifying U.S. small business.

Administratively, the opportunity is categorized as discretionary and uses a grant funding instrument. The NIH is the sponsoring agency. The original closing date listed is September 6, 2023, and the opportunity was created on January 30, 2023. The listed award ceiling is $295,924, indicating the maximum award amount anticipated under this announcement (applicants would still need to align their budgets with SBIR rules, the project scope, and NIH guidance). Multiple CFDA numbers are associated with the announcement (including 93.121, 93.233, 93.273, 93.286, 93.307, 93.350, 93.837, 93.838, 93.839, 93.840, 93.847, 93.853, 93.866), reflecting the NIH’s multiple institutes and program areas that can align with minority health and health disparities work.

Overall, this FOA is best suited for U.S. small businesses developing scalable health-related innovations that are explicitly designed to reduce disparities, not just improve health in general. Competitive proposals will typically make a clear case that the innovation addresses a disparity-affected population group, is designed with cultural and affordability considerations in mind, and has a believable path to commercialization and real-world impact.

• The National Institutes of Health in the food and nutrition, health sector is offering a public funding opportunity titled "Innovations for Healthy Living - Improving Minority Health and Eliminating Health Disparities (R43/R44 - Clinical Trial Optional)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.121, 93.233, 93.273, 93.286, 93.307, 93.350, 93.837, 93.838, 93.839, 93.840, 93.847, 93.853, 93.866.
• This funding opportunity was created on 2023-01-30.
• Applicants must submit their applications by 2023-09-06. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $295,924.00 in funding.
• Eligible applicants include: Small businesses.

Apply for RFA MD 23 003

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: